Andrew Hollman Meyer - Dec 19, 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Business Officer
Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Dec 19, 2024
Transactions value $
$199,985
Form type
4
Date filed
12/20/2024, 06:25 PM
Previous filing
Sep 27, 2024
Next filing
Jan 3, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Options Exercise $200K +9.88K +14.62% $20.24 77.5K Dec 19, 2024 Direct
transaction JANX Common Stock Options Exercise $14.00 +1 +0% $14.02 77.5K Dec 19, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -9.88K -9.26% $0.00 96.9K Dec 19, 2024 Common Stock 9.88K $20.24 Direct F1
transaction JANX Stock Option (right to buy) Options Exercise $0 -1 0% $0.00 90K Dec 19, 2024 Common Stock 1 $14.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on January 1, 2023 and the balance vests in equal monthly installments thereafter over a three year period.
F2 25% of the shares subject to the option vested on January 1, 2024 and the balance vests in equal monthly installments thereafter over a three year period.